Consolidative thoracic radiation could not improve survival of extensive-stage small-cell lung cancer with first-line chemoimmunotherapy: results from a single cancer center
Abstract Objective To investigate the role of consolidative thoracic radiation (TRT) in extensive-stage small-cell lung cancer (ES-SCLC) receiving first-line chemo-immunotherapy followed by immunotherapy maintenance. Patients and Methods: Outcomes of patients without disease progression after first-line chemotherapy were reviewed (January 2020 to December 2021). Based on TRT or not, patients were allocated to TRT group or non-TRT group. Progression-free survival (PFS), overall survival (OS) and local-recurrence free survival (LRFS) were calculated by the Kaplan-Meier method and compared by log-rank test. Results Of 100 patients, 47 received TRT and 53 non-TRT. The median follow-up was 20.3 months. The median PFS and OS in TRT were 9.1 months and 21.8 months, versus 8.8 months (p = 0.93) and 24.3 months (p = 0.63), respectively, in non-TRT. The median LRFS time in TRT was not reached, but significantly longer than 10.8 months in non-TRT (HR = 0.27, p < 0.01). Second-line chemotherapy significantly prolonged survival compared to that with chemo-free patients (mOS: 24.5 vs. 21.4 months, p = 0.026). The subgroup analysis showed a trend of patients with brain metastases benefit from TRT (21.8 versus 13.7 months, HR 0.61, p = 0.38) while liver metastases did not. Of 47 patients with TRT, only 10.6% of patients experienced grade 3 radiation-induced pneumonitis, while no grade 4 or 5 adverse events occurred. Conclusion Consolidative TRT in the period of immunotherapy maintenance followed first-line chemo-immunotherapy did not prolong OS and PFS but increased LRFS in ES-SCLC..
Medienart: |
Preprint |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
ResearchSquare.com - (2023) vom: 31. Jan. Zur Gesamtaufnahme - year:2023 |
---|
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Li, Yuying [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
Themen: |
---|
doi: |
10.21203/rs.3.rs-2468046/v1 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
XRA038421178 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | XRA038421178 | ||
003 | DE-627 | ||
005 | 20230429195233.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230117s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.21203/rs.3.rs-2468046/v1 |2 doi | |
035 | |a (DE-627)XRA038421178 | ||
035 | |a (ResearchSquare)10.21203/rs.3.rs-2468046/v1 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Li, Yuying |e verfasserin |4 aut | |
245 | 1 | 0 | |a Consolidative thoracic radiation could not improve survival of extensive-stage small-cell lung cancer with first-line chemoimmunotherapy: results from a single cancer center |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Abstract Objective To investigate the role of consolidative thoracic radiation (TRT) in extensive-stage small-cell lung cancer (ES-SCLC) receiving first-line chemo-immunotherapy followed by immunotherapy maintenance. Patients and Methods: Outcomes of patients without disease progression after first-line chemotherapy were reviewed (January 2020 to December 2021). Based on TRT or not, patients were allocated to TRT group or non-TRT group. Progression-free survival (PFS), overall survival (OS) and local-recurrence free survival (LRFS) were calculated by the Kaplan-Meier method and compared by log-rank test. Results Of 100 patients, 47 received TRT and 53 non-TRT. The median follow-up was 20.3 months. The median PFS and OS in TRT were 9.1 months and 21.8 months, versus 8.8 months (p = 0.93) and 24.3 months (p = 0.63), respectively, in non-TRT. The median LRFS time in TRT was not reached, but significantly longer than 10.8 months in non-TRT (HR = 0.27, p < 0.01). Second-line chemotherapy significantly prolonged survival compared to that with chemo-free patients (mOS: 24.5 vs. 21.4 months, p = 0.026). The subgroup analysis showed a trend of patients with brain metastases benefit from TRT (21.8 versus 13.7 months, HR 0.61, p = 0.38) while liver metastases did not. Of 47 patients with TRT, only 10.6% of patients experienced grade 3 radiation-induced pneumonitis, while no grade 4 or 5 adverse events occurred. Conclusion Consolidative TRT in the period of immunotherapy maintenance followed first-line chemo-immunotherapy did not prolong OS and PFS but increased LRFS in ES-SCLC. | ||
650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
700 | 1 | |a Jing, Wang |e verfasserin |4 aut | |
700 | 1 | |a Jing, Xuquan |e verfasserin |4 aut | |
700 | 1 | |a Sun, Yulan |e verfasserin |4 aut | |
700 | 1 | |a Tang, Xiaoyong |e verfasserin |4 aut | |
700 | 1 | |a Guo, Jun |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Yan |e verfasserin |4 aut | |
700 | 1 | |a Zhu, Hui |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t ResearchSquare.com |g (2023) vom: 31. Jan. |
773 | 1 | 8 | |g year:2023 |g day:31 |g month:01 |
856 | 4 | 0 | |u http://dx.doi.org/10.21203/rs.3.rs-2468046/v1 |z kostenfrei |3 Volltext |
912 | |a GBV_XRA | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |j 2023 |b 31 |c 01 |